NAP1/BI/027

NAP1/BI/027
Name	NAP1/BI/027
Taxon	Clostridioides difficile
Strain type	Hypervirulent strain
First identified	2000s
Associated disease	Severe C. difficile infection

NAP1/BI/027 is a hypervirulent strain of the bacterium Clostridioides difficile, first identified in the early 21st century and associated with severe outbreaks of healthcare-associated infection. It is characterized by increased toxin production, resistance to fluoroquinolone antibiotics, and high morbidity and mortality rates. This strain has been a major driver of epidemics in North America, Europe, and other regions, significantly impacting hospital infection control protocols.

Overview and Classification

NAP1/BI/027 represents a specific ribotype (027) within the broader species Clostridioides difficile, a Gram-positive, spore-forming anaerobe. The designation "NAP1" refers to its North American Pulsed-field type, while "BI" indicates its identification by the Centers for Disease Control and Prevention typing method. This strain is part of a clonal lineage that has rapidly disseminated globally, often referred to in conjunction with other epidemic strains like ribotype 078. Its classification is central to surveillance efforts by public health agencies such as the European Centre for Disease Prevention and Control.

Epidemiology and Transmission

The epidemiology of this strain is marked by its emergence in the early 2000s, with significant outbreaks reported in Quebec, Pittsburgh, and across the United Kingdom. Transmission occurs primarily in healthcare settings like hospitals and long-term care facilities through the fecal-oral route, facilitated by the environmental persistence of its spores. Factors contributing to its spread include high rates of asymptomatic carriage, suboptimal infection control practices, and the widespread use of certain antibiotics. Major outbreaks have been documented by the World Health Organization and national bodies like Public Health England.

Clinical Significance and Disease

Infection with this strain is associated with more severe Clostridioides difficile infection, including a higher incidence of fulminant colitis, toxic megacolon, and recurrent disease. Patients often present with profound leukocytosis, acute kidney injury, and require admission to intensive care units. Mortality rates are significantly elevated compared to infections caused by historical strains. The severity of illness has prompted changes in clinical management guidelines, often involving early surgical consultation and the use of novel therapies like fidaxomicin and bezlotoxumab.

Molecular Characteristics and Virulence

The hypervirulence of this strain is attributed to key genetic mutations and increased toxin production. It possesses a deletion in the *tcdC* gene, a negative regulator of toxin expression, leading to overproduction of toxins TcdA and TcdB. Additionally, it carries genes for binary toxin (CDT), whose role in pathogenesis is an active area of research. The strain also exhibits high-level resistance to fluoroquinolones such as ciprofloxacin and moxifloxacin, conferred by mutations in DNA gyrase. These molecular traits were elucidated through sequencing efforts at institutions like the Wellcome Sanger Institute.

History and Discovery

The strain was first identified as a cause of major outbreaks in the early 2000s, with seminal reports published in journals like *The New England Journal of Medicine* describing epidemics in Montreal and the Northeastern United States. Its rapid rise challenged existing paradigms about Clostridioides difficile as a predominantly hospital-acquired pathogen. Investigations traced its emergence to the selective pressure of fluoroquinolone use and possible interspecies transfer from agricultural animals. The 2009 flu pandemic period saw heightened surveillance and recognition of its global spread.

Prevention and Control

Prevention and control strategies are multifaceted, emphasizing strict contact precautions, enhanced environmental disinfection with sporicidal agents like hypochlorite, and antimicrobial stewardship to reduce unnecessary cephalosporin and fluoroquinolone use. Diagnostic stewardship utilizing tests like nucleic acid amplification tests and enzyme immunoassays is critical for accurate detection. Infection prevention bundles promoted by the Society for Healthcare Epidemiology of America are widely implemented. Research into vaccine development and the use of fecal microbiota transplantation represents a growing frontier in managing and preventing recurrence.

Category:Clostridioides difficile Category:Infectious diseases Category:Bacterial strains